Monte Rosa Therapeutics has shared positive interim data from an ongoing Phase I clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6. “These remarkable interim data from our ongoing Phase I study of… Read More
Eli Lilly has agreed to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on developing oral therapies for patients with inflammatory-mediated diseases. Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high… Read More
Biotechnology company Nucleome Therapeutics is set to advance a potential first-in-class treatment for major chronic inflammatory diseases. NTP464 is a potential first-in-class monoclonal antibody agonist with strong potency, selectivity and developability characteristics. Nucleome has nominated NTP646 for development. The target of NTP464 is a novel inflammation checkpoint identified using Nucleome’s proprietary suite of… Read More
Earendil Labs and Sanofi have agreed a strategic collaboration to apply Earendil’s discovery platform to multiple autoimmune and inflammatory disease programmes. Sanofi will lead the development and worldwide commercialisation of bispecific candidates arising from the collaboration. According to the agreement Earendil Labs will receive up… Read More
Monte Rosa Therapeutics has dosed the first subjects in a Phase I study evaluating MRT-8102, a NEK7-directed molecular glue degrader (MGD) being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6. Initial results from the Phase I study are expected in… Read More
Domain Therapeutics has announced plans to progress DT-9046, a candidate it says has game-changing potential in multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine. PAR2 has emerged as a pivotal therapeutic in inflammatory diseases due to its… Read More
Maxion Therapeutics has raised $72 million in an oversubscribed Series A Financing to advance its antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases. The financing was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and… Read More
A new start-up aimed at discovering and developing anti-inflammatory disease medicines has been formed by The University of Queensland’s commercialisation arm UniQuest and global biotech company Molecule to Medicine (MTM). Curlew Bio will leverage expertise from the Queensland Emory and Drug Discovery Initiative (QEDDI) and research developed… Read More
Simona E Carbone, Michelle P Papadimitriou and Darren J Kelly, discuss why GPR68 has been considered an attractive target for cancer therapy – albeit difficult to drug – and highlight its exciting potential in the development of drugs to treat a range of inflammatory and fibrotic diseases. GPR68, or OGR1,… Read More
Gilead Sciences and LEO Pharma have agreed a strategic partnership to accelerate the development of LEO Pharma’s small molecule STAT6 programmes for inflammatory diseases. STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signalling, which are clinically validated targets for Th2 mediated inflammatory conditions… Read More
The discovery of a new regulator affecting immune cells could lead to new treatments to reduce inflammation in diseases including arthritis and severe Covid-19. A large research collaboration, led by the University of Exeter’s MRC Centre for Medical Mycology, has focused on how immune cells sense… Read More
Oncodesign Precision Medicine (OPM) has announced positive results of a Phase I trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV). OPM-101 is intended for the treatment of resistant and metastatic cancers. Read More
Kynos Therapeutics has announced positive top line results from the first in human Phase I trial of its lead drug candidate, KMO inhibitor KNS366, for acute and chronic inflammatory disorders. KMO is an enzyme that acts at a key point in the kynurenine pathway of… Read More
Gilead Sciences has opened a new research site at the Business Park in Oxford, UK. With capacity for up to 60 research scientists and employees, the company says the site will play a role in helping to drive innovation in the UK life sciences sector, with… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revolo Biotherapeutics’ ‘1104 to treat eosinophilic esophagitis (EoE). EoE is a chronic, allergic inflammatory disease that is characterised by the accumulation of eosinophils in the lining of the esophagus. Inflammation caused by immune… Read More
Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). The antibody, called Ab-IPL-IL-17, targets a specific section of signalling proteins IL-17A and IL-17F… Read More
